Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Themis will market this drug with the brand name REMITHEM.
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Subscribe To Our Newsletter & Stay Updated
